Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

2.8K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.8K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

502
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
502

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choroidal Thickness May Shed Light on Early Coronary Artery Disease.

Nigerian journal of clinical practice·2026
Same author

Critical organ dose evaluation during interventional stroke imaging: Implications for radiation safety.

Radiography (London, England : 1995)·2026
Same author

Evaluation of Cranial Computed Tomography use and Guideline Compliance in Head Trauma Patients Presenting to the Emergency Department.

Nigerian journal of clinical practice·2025
Same author

Evaluation of Basal Ganglia in Paediatric Patients With Primary Nephrotic Syndrome by Brain Magnetic Resonance Histogram Analysis.

Nigerian journal of clinical practice·2024
Same author

Effort-based decision-making in ultra-high-risk for psychosis and bipolar disorder.

Psychological medicine·2024
Same author

Tranexamic Acid and Tourniquet: Which Combination Reduces Blood Loss Most Effectively?

Nigerian journal of clinical practice·2024

Related Experiment Video

Updated: Apr 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Does the inhibition of renin-angiotensin system decrease inter-dialytic weight gain in anuric hemodialysis patients?

A Kutlucan1, M Demir, Y Turker

  • 1Department of Internal Medicine, Faculty of Medicine, Selcuk University, Konya, Turkey. dralikutlucan@gmail.com.

European Review for Medical and Pharmacological Sciences
|January 31, 2015
PubMed
Summary

Telmisartan significantly reduced inter-dialytic weight gain (IDWG) and improved echocardiographic measurements, including left ventricular end-diastolic diameter (LVEDD) and inferior vena cava diameter (IVCD), in anuric hemodialysis patients.

More Related Videos

Use of a Hanging-weight System for Isolated Renal Artery Occlusion
07:54

Use of a Hanging-weight System for Isolated Renal Artery Occlusion

Published on: July 19, 2011

16.7K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
Use of a Hanging-weight System for Isolated Renal Artery Occlusion
07:54

Use of a Hanging-weight System for Isolated Renal Artery Occlusion

Published on: July 19, 2011

16.7K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Limited data exists on the effects of lipophilic Angiotensin-II (AT-II) receptor blockers on central AT-II receptors.
  • Central AT-II receptors play a role in fluid balance and cardiovascular regulation.

Purpose of the Study:

  • To investigate the impact of Telmisartan on inter-dialytic weight gain (IDWG) and echocardiographic parameters in anuric hemodialysis (HD) patients.
  • To assess the effects of Telmisartan, a highly lipophilic AT-II receptor blocker, on fluid management and cardiac structure in HD patients.

Main Methods:

  • A prospective, randomized, self-controlled study involving 41 anuric HD patients.
  • Patients received Telmisartan 40 mg/day for three months after a four-week washout period of previous antihypertensive medications.
  • Assessments included IDWG and echocardiographic measurements (LVEDD, IVCD, LVMI) at baseline, after three months without Telmisartan, and after three months with Telmisartan.

Main Results:

  • Telmisartan significantly reduced IDWG % compared to the period without the drug (5.6 ± 1.0% vs 5.3 ± 1.0%, p = 0.03).
  • Significant decreases in left ventricular end-diastolic diameter (LVEDD) and inferior vena cava diameter (IVCD) were observed after Telmisartan administration (p = 0.001 for both).
  • Left ventricular mass index (LVMI) also significantly regressed following Telmisartan treatment (269.3 ± 82.7 g vs 256.3 ± 70.3 g, p = 0.003).

Conclusions:

  • Daily 40 mg Telmisartan treatment effectively reduces IDWG, LVEDD, and IVCD in anuric HD patients.
  • These findings suggest a beneficial role for Telmisartan in managing fluid overload and cardiac remodeling in this patient population.
  • Further research is warranted to explore the long-term clinical outcome benefits of Telmisartan therapy in anuric HD patients.